Description
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.
Cat.No
A742
Name
Inebilizumab Biosimilar（Anti-CD19 Reference Antibody）
Chemical Properties
CAS
1299440-37-1
Synonyms
VIB 551;MEDI 551;Uplizna;Inebilizumab-cdon;Inebilizumab;Research Grade Inebilizumab(DHD10802);Research Grade Inebilizumab(DHD10802);Inebilizumab (anti-CD19);Inebilizumab (anti-CD19);MEDI 551|||MT-0551|||16C4-aFuc|||VIB-0551;MEDI 551|||MT-0551|||16C4-aFuc|||VIB-0551
pH value
Corresponds to reference standard: PASS
Non-reduced CE-SDS
>95%
SEC-HPLC
>95%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard: PASS
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131Fax: +86-21-61642470Email:
Website:
